BioSig to Host Conference Call on Recent Developments of Subsidiary ViralClear and its Broad-Spectrum Oral Anti-Viral Candidate Merimepodib for the Treatment of COVID-19 April 24, 2020
BioSig Subsidiary ViralClear Submits Investigational New Drug Application to the FDA for Phase II Clinical Trials for Merimepodib, an Orally Administered Treatment for Patients with COVID-19 April 24, 2020
Tony Zook Joins the Board of ViralClear Pharmaceuticals, a majority-owned subsidiary of BioSig Technologies, Inc. April 21, 2020
BioSig Subsidiary ViralClear Submits Application for Vicromax™ Through FDA’s Coronavirus Treatment Acceleration Program (CTAP) to Seek Acceleration of its Planned Clinical Trials April 21, 2020
Mayo Clinic Preparing to Commence Phase II FDA Clinical Trial for the Treatment of COVID-19 with Vicromax™ April 16, 2020
Positive Data Generated by BioSig Subsidiary ViralClear on COVID-19 Coronavirus Published in bioRxiv April 9, 2020
BioSig to Host Telebriefing on Development Updates Regarding Vicromax(tm), a Novel Broad-Spectrum Anti-Viral Candidate That May Treat COVID-19 April 3, 2020
Jerome Zeldis, M.D., Ph.D, Appointed as Executive Chair of ViralClear Pharmaceuticals, Inc. March 31, 2020
BioSig subsidiary NeuroClear acquires license for a broad-spectrum anti-viral agent that may treat COVID-19. Laboratory results demonstrate high level of activity against COVID-19 in cell culture March 25, 2020
